Logo
x

Search

Subscribe Now

T2D

AstraZeneca's Forxiga (dapagliflozin) Receives EC's Approval for the Treatment of Chronic Kidney Disease in Patients with and without T2D

AstraZeneca's Forxiga (dapagliflozin) Receives EC's Approval for the Treatment of Chronic Kidney Disease in Patients with and with...

  • August 9, 2021
Novo Nordisk Receives the US FDA's Refusal to File Letter for Semaglutide to Treat T2D

Novo Nordisk Receives the US FDA's Refusal to File Letter for Semaglutide to Treat T2D

  • March 23, 2021
Bayer Reports the US FDA's Acceptance of NDA and Grants Priority Review for Finerenone (BAY 94-8862) to Treat CKD and T2D

Bayer Reports the US FDA's Acceptance of NDA and Grants Priority Review for Finerenone (BAY 94-8862) to Treat CKD and T2D

  • January 13, 2021
Teladoc Health and Dexcom Offers CGM-Powered Insight for T2D

Teladoc Health and Dexcom Offers CGM-Powered Insight for T2D

  • January 13, 2021
Novo Nordisk Reports Submission of Label Extension Application to the EMA for Semaglutide (once weekly- 2.0 mg) for T2D

Novo Nordisk Reports Submission of Label Extension Application to the EMA for Semaglutide (once weekly- 2.0 mg) for T2D

  • December 30, 2020
Bayer Reports Regulatory Submission of Finerenone (BAY 94-8862) to the US and EU for CKD and T2D

Bayer Reports Regulatory Submission of Finerenone (BAY 94-8862) to the US and EU for CKD and T2D

  • November 10, 2020
Roche Reports the P-I (CT-996-201) Study Data of CT-996 for Treating Obesity

    Roche Reports the P-I (CT-996-201) Study Data of CT-996 for Treating Obesity

    • July 17, 2024
    Eli Lilly Reports Data from Two P-III (QWINT-2 and QWINT-4) Studies of Efsitora for Treating Type 2 Diabetes

      Eli Lilly Reports Data from Two P-III (QWINT-2 and QWINT-4) Studies of Efsitora for Treating Type 2 Diabetes

      • May 16, 2024
      Roche Reveals Results from the P-I Clinical Evaluation of CT-388 for Treating Obesity and Type 2 Diabetes

        Roche Reveals Results from the P-I Clinical Evaluation of CT-388 for Treating Obesity and Type 2 Diabetes

        • May 16, 2024
        Innovent Biologics Reports the P-III Trial Results of Mazdutide for Treating Type 2 Diabetes

          Innovent Biologics Reports the P-III Trial Results of Mazdutide for Treating Type 2 Diabetes

          • May 9, 2024
          Helen Yeh & Naim Shehadeh in a Stirring Conversation with PharmaShots, Highlight the Results from T2NOW Study

            Helen Yeh & Naim Shehadeh in a Stirring Conversation with PharmaShots, Highlight the Results from T2NOW Study

            • December 11, 2023
            Inventiva Reports the US FDA’s Acceptance of IND for Review of Lanifibranor and Empagliflozin for the Treatment of NASH and T2D

              Inventiva Reports the US FDA’s Acceptance of IND for Review of Lanifibranor and Empagliflozin for the Treatment of NASH and T2D

              • March 9, 2022
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.